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Abstract 27 
Background: Stereotactic biopsy is consistently employed to characterize cerebral lesions in patients 28 
who are not suitable for microsurgical resection. In the past years technical improvement and 29 
neuroimaging advancements contributed to increase the diagnostic yield, the safety and the application 30 
of this procedure. Currently, in addition to histological diagnosis, the molecular analysis is considered 31 
essential in the diagnostic process to properly select therapeutic and prognostic algorithms in a 32 
personalized approach. The present study reports our experience with frameless stereotactic brain 33 
biopsy in this molecular era.  34 
 35 
Methods: 140 consecutive patients treated from January 2013 to September 2018 were analyzed. 36 
Biopsies were performed using the Brainlab Varioguide® frameless stereotactic system. Patients’ 37 
clinical and demographic data, the time of occupation of the operating room, the surgical time, the 38 
morbidity and the diagnostic yield in providing a histological and molecular diagnosis were recorded 39 
and evaluated. 40 
 41 
Results: The overall diagnostic yield was 93.6% with 9 procedures resulting non-diagnostic. Among 42 
110 patients with glioma, the IDH-1 mutational status was characterized in 108 cases (98.2%), 43 
resulting wild-type in all subjects but 3; MGMT methylation was characterized in 96 cases (87.3%), 44 
resulting present in 60 patients and 1p/19q codeletion was founded in 6 of the 20 cases of grade II-III 45 
gliomas analyzed. All the specimens were apt for molecular analysis when performed. Bleeding 46 
requiring surgical drainage occurred in 2.1% of the cases; 8 (5.7%) asymptomatic hemorrhages 47 
requiring no treatment were observed. No biopsy-related mortality was recorded. Median length of 48 
hospital stay was 5 days (IQR 4-8) with mean surgical time of 60.77 minutes (±23.12) and 137.44 49 
±24.1 minutes of total occupation time of the operative room.  50 
 51 
Conclusions: Stereotactic frameless biopsy is a safe, feasible and fast procedure to obtain a 52 
histological and molecular diagnosis. 53 
 54 
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Introduction 58 
Stereotactic biopsy is a robust technique, representing one of the most important and minimally 59 
invasive procedure to characterize lesions of the central nervous system in vivo [8, 31, 35].  60 
Since its inception, this technique progressively developed from frame-based [2, 3] to frame-less  (or 61 
less framed) setup [4–6] with the aid of instrument holders, trajectory guides, lockable or robotic arms 62 
[7, 24] to grant accurate targeting and to ease the workflow. 63 
Despite the frame-based technique is still considered the gold-standard for a stereotactic approach to 64 
the brain, frame-less devices progressively evolved. Frame-based techniques are considered 65 
troublesome by several factors, such as frame structure, patient’s discomfort, imaging after frame 66 
placement, calculations of the entry point, prolonged surgical time and risk of infection at the frame’s 67 
fixture points [34]. Therefore, frame-less procedure have been becoming a useful choice for their 68 
easiness of use and comparable diagnostic yield [1, 16]. 69 
Neuroimaging advancements further benefited the stereotactic approach, contributing to increase both 70 
the diagnostic yield and the safety by allowing accurate planning and intraoperative check of sampling 71 
at the correct target with several approaches [11, 32, 45]. Both morphological and metabolic imaging, 72 
such as conventional and advanced MRI [14, 39] and positron-emission tomography (PET) with 73 
dedicated radiotracers [26]can now be co-registered and uploaded in the navigation system and used as 74 
image-guidance to target the most informative lesion area and thus grant an optimal diagnosis.  75 
In fact, when microsurgical resection is not indicated, stereotactic biopsy is crucial for obtaining a 76 
definite histopathologic diagnosis in order to select the appropriate therapeutic modality for a specific 77 
patient and his/her pathology.  78 
In addition to histopathology, recent refinements of the World Health Organization (WHO) 79 
Classification of Tumors of the Central Nervous System (CNS) established the need of stratification 80 
through molecular features [19, 27, 37] for a conclusive diagnosis. In particular, the status of isocitrate 81 
dehydrogenase (IDH) 1 and 2, the co-deletion of complete chromosome arms 1p and 19q and the 82 
methylation status of the O6-methylguanine-DNA-methyltransferase (MGMT) gene are the most 83 
relevant molecular markers for glioma characterization [9, 18, 19]. As therapeutic options become 84 
increasingly depending upon molecular features for both clinical and experimental management, an 85 
accurate and precise integrated histo-molecular diagnosis is thus mandatory, especially in a time where 86 
precision medicine looms. 87 
Previous studies explored the feasibility, safety, experimental and clinical accuracy of a frame-less 88 
system with a lockable arm with real-time visual feedback of the target area [38] when diagnosis for 89 
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glioma was based on a previous WHO classification exclusively based on histological features . We 90 
herein reported a study expanding previous experiences of the stereotactic biopsy in the updated 91 
context of a molecular era of neuro-oncology. In particular, this study was conceived to assess the 92 
performance of the frameless stereotactic biopsy in providing tissue samples appropriate to meet both 93 
the histological and molecular demands of the updated diagnostic criteria of the 2016 WHO CNS 94 
tumors classification.  95 
96 
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 97 
Materials and Methods 98 
Subjects 99 
One hundred and forty (140) adult subjects affected by a lesion of unknown etiology affecting the brain 100 
not amenable of microsurgical resection, as established by the consultant neurosurgeons either 101 
independently or during weekly institutional neuro-oncology group discussions, were prospectively 102 
enrolled from January 2013 to August 2018 [Figure 1]. All patients signed an informed consent for the 103 
procedure. No patients underwent open surgical treatment or radiation therapy before the bioptic 104 
procedure. Demographic, clinical and pathological features were collected, along with surgical and 105 
pathological data [Tables 1- 3]. Histology was classified according to the 2016 WHO brain tumor 106 
classification [27]. 107 
 108 
Neuroradiological Protocol and Image processing 109 
MR imaging was performed on a 3 Tesla MR scanner (Siemens Verio, Germany), as previously 110 
described [40]. Lesion volumes were computed onto volumetric sequences with a semiautomatic 111 
segmentation method using iPlan Cranial 3.0 (Brainlab AG, Munich, Germany). 11-C-MET-PET was 112 
available for “hot-spot” identification in 49 patients (35%), serving as additional hint for the 113 
appropriate selection of the target [26]. The pre-operative MR and PET imaging dataset was co-114 
registered with a CT scan, where 7 radiopaque fiducials were applied. CT and MRI were performed 115 
within 24 hours of surgery. The co-registered datasets were uploaded to the neuronavigation system 116 
and registration was based on fiducials. A post-operative CT scan was performed to rule out any acute 117 
complication.  118 
Biopsy targets and entry points were planned on MRI with contrast enhancement and 11-C-MET-PET 119 
hot spots, when available. In order to avoid larger vessel damage, trajectories were controlled for any 120 
crossing vessels in contrast enhanced volumetric MR images. Targeted lesion volumes and trajectory 121 
length, from dura mater to the target, were measured.  122 
 123 
Frameless Stereotactic Biopsy 124 
Patients were operated on general anesthesia. After placement in the 3-point Mayfield head clamp, the 125 
procedure was performed under navigation guidance with on-site planning. The surgical plan (entry 126 
point, biopsy target, and needle trajectory) was determined using Brainlab navigation software module 127 
within the Cranial application. After accuracy of the system was confirmed, a burr hole was placed, and 128 
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biopsy samples were obtained with image-guidance using Brainlab Varioguide® frameless stereotactic 129 
brain biopsy system; a pre-calibrated needle with 2 reflective markers is inserted through the lockable 130 
stereotactic arm with 3 rotational joints, serving as trajectory guide. The navigation system provided a 131 
real-time visual feedback of the position of the sampling window; the system is a not-rigid device 132 
allowing to change the trajectory in any moment during the procedure, if needed [Figure 2].  133 
All tissue samples were verified by a pathologist attending the operating room. In each procedure, the 134 
samples extraction was continued until the quantity and the quality of the tissue taken were considered 135 
suitable for definitive analysis by the pathologist. Time of occupation of the operating room and the 136 
surgical time, from skin incision to suture, were recorded. Both histological and molecular features 137 
were collected and stored prospectively. No retrospective pathological re-assessment of previously 138 
acquired samples were performed. 139 
 140 
 141 
Statistical Analysis 142 
The statistical analysis and the collection of data were performed with IBM SPSS Statistics 22.0 for 143 
Mac software (SPSS Inc., Chicago, IL, USA). Continuous variables were reported as mean ± standard 144 
deviation (SD) or median plus the range between the minimum and the maximum value or the 145 
interquartile range (IQR). Continuous variables were compared with a Student’s t-test and categorical 146 
variables were compared with the Fisher exact test. We considered, as statistically significant, a two-147 
tailed P-value < 0.05. 148 
 149 
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Results 150 
 151 
Demographic and lesions characteristics  152 
One hundred and forty patients (73 males, 67 females) underwent the stereotactic frameless procedure. 153 
Mean age was 58.6 years (±15.3). Median performance status (KPS) was 90%, ranging from 40-100%.  154 
Median length of hospital stay was 5 days (IQR 4-8). Lesion sites are reported in Table 1 and lesion 155 
volumes are reported in Table 2.  156 
 157 
Frameless stereotactic biopsy 158 
Targets were selected onto MRI. The mean trajectory length was 46.04 mm (±32.54) and ranged from 159 
8.5 to 140 mm, measured from cortical entry to the target. A single needle pass was used for sequential 160 
biopsies taken along the trajectory in all cases but 3; 84 (60%) and 56 (40%) cases were approached 161 
from the left and right side, respectively. Nine posterior fossa lesions (6.4%), in particular, were 162 
approached through a retro-sigmoidal burr-hole. 163 
The surgical procedure lasted 60.5 minutes on average (±23.1), measured from skin incision to 164 
complete suture. The time spent in the operating room, measured from patient entry to the exit, was 165 
137.44 ± 24.1 minutes. 166 
 167 
Integrated Histo-molecular diagnosis  168 
The overall diagnostic yield was 93.6%: a definitive histological diagnosis was obtained in 131 169 
patients. Grade IV, III and II gliomas were reported in 76 (69.1%), 15 (13.6%) and 6 (5.5%) cases, 170 
respectively; glioma not otherwise specified (NOS) was reported in 12 (10.9%) subjects. A B-cell Non-171 
Hodgkin lymphoma was diagnosed in 13 (11.8%) patients; 2 (1.8%) cases of abscess and 2 of germ-172 
cell tumor were reported. One metastasis from melanoma and a colloid cyst were also diagnosed. The 173 
final pathology report resulted inconclusive in 9 cases (6.4%). In this group, 5 out of 8 patients had a 174 
11-C-MET-PET available for the biopsy planning. No differences (p>0.05) were recorded in the 175 
diagnostic yield dividing the sample by gender, median age, lesion site and 11-C-MET-PET 176 
availability.  177 
Considering the new classification of the WHO, the power to characterize 3 relevant molecular 178 
determinants of gliomas, such as IDH status, 1p and 19q codeletion and MGMT methylation, was also 179 
analyzed when applicable. The IDH-1 status was characterized in 108 cases (98.2 % in the glioma 180 
group), resulting wild-type in all subjects but 3; MGMT methylation was characterized in 96 cases 181 
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(87.3%), resulting present in 60 patients, and absent in 36 cases. 1p/19q codeletion was founded in 6 of 182 
the 20 cases of lower grade gliomas (i.e. grade II and III) where the material provided by the biopsy 183 
was successfully analyzed in 100% of the cases.  184 
 185 
Morbidity 186 
An asymptomatic intracerebral hemorrhage (ICH), detected by routine post-operative CT scan and 187 
requiring mere observation, occurred in 8 (5.7%) patients. A symptomatic ICH requiring surgical 188 
drainage occurred in 3 cases (2.1%), with no permanent neurological dysfunction at follow-up. No in-189 
hospital or 30-day mortality were recorded.  There was not statistically significant correlation between 190 
the number and the occurrence of surgical complication and the patient’s sex, age (using the median 191 
age of 60yr) and the location of the hemispherical tumors (superficial versus deep location).  192 
We did not observe any statistical significant difference between the numbers of complication in 193 
patients underwent surgery from January 2013 to April 2016 (6 cases) and patients underwent the 194 
procedure from April 2016 to July 2018 (2 cases). 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
 203 
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 208 
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Discussion 211 
 212 
The aim of stereotactic biopsy is to provide the diagnosis of a cerebral lesion of unknown etiology in an 213 
easy, safe and fast way. In the present study, we reviewed all the biopsies performed in our institute 214 
from January 2013 to August 2018. We analyzed the safety and the diagnostic yield according to the 215 
new 2016 WHO CNS tumors classification of the frameless stereotactic biopsy using the Varioguide 216 
system to provide essential histological and molecular features. Bradac et al, in a recent prospective 217 
and randomized study, showed that the frameless biopsy procedure has the same trajectory accuracy, 218 
rate of complications and diagnostic yield of the frame-based technique that is still now considered the 219 
gold-standard. Although they showed that the frameless biopsy is better accepted and tolerated by the 220 
patients [10], a conclusive argument about tolerance to either frame-based or frameless technique is 221 
still controversial.  222 
In the past years a lot of studies showed the importance of adding the molecular data to the histological 223 
and morphological evaluation for a better prognostic and therapeutic characterization of patients with 224 
tumors of the central nervous system. The data supporting these evidences were so strong that the 225 
molecular markers are currently essential in the new 2016 classification of the central nervous system 226 
tumors [27]. In particular, to characterize a glial tumor, the pathologist employs the status of mutation 227 
of IDH1/2, the 1p/19q codeletion and the MGMT promoter methylation [9, 18, 19, 26, 37, 42]. 228 
Therefore, we focused our analyses on the histological result of the glial lesions and related molecular 229 
investigations, thus expanding previous findings of the performance of the stereotactic biopsy in 230 
contemporary neuro-oncology[29]. 231 
We obtained a diagnostic yield, defined as “the likelihood that a test or procedure will provide the 232 
information needed to establish a diagnosis” [22], of  93.6%. This data is comparable to others reported 233 
by different authors [17, 20, 33, 38, 44, 45] . For example, Khatab et al [22] reviewed 16 different 234 
works in which 1628 frameless biopsy procedures were analyzed whit an average diagnostic yield of  235 
93.8% (range 87-100%).  Similar result are reported, for example, by Lu et al [28] with a diagnostic 236 
yield with frameless biopsies of 91.8%, also without any statistical significant difference in comparison 237 
to frame-based biopsies (96.9%), and intraoperative MRI guided biopsies (89.9%). In addition, these 238 
results independently confirming previous results of the application of stereotactic frameless biopsy in 239 
the context of the 2016 WHO CNS tumors classification, thus providing more evidence for supporting 240 
the clinical practice[29].  241 
We did not find any demographic or lesion characteristics associated more likely to a diagnostic yield; 242 
in particular there was no association with the gender, median age, lesion site. We did not found any 243 
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statistically significant association even with the availability of 11-C-MET-PET for “hot spot” targeting 244 
and the diagnostic yield. [25, 36] The use of stereotactic PET may increase the diagnostic yield of brain 245 
biopsy, like showed in several previous studies, but our data doesn’t’ show this correlation. The lack of 246 
association between the diagnostic yeld and all the demographic, tumoral and availability of PET can 247 
be likely explained by the relative low prevalence of non-diagnostic procedure in our semple.  Khatab 248 
et al showed that patients younger than 30 years were more likely to obtain a non-diagnostic biopsy. 249 
Other reported predictive factors for non-diagnostic biopsies were right-sided lesions, long surgical 250 
time  and the number of biopsy for single patient [17]. All the procedures were performed with a 251 
pathologist attending the operating room. Dammers et al, in fact, showed that the intraoperative frozen-252 
section analysis statistically improved the diagnostic yield, the number of biopsies needed and the 253 
operating time [16].  Although a control group was not available, the high diagnostic yield in the 254 
current series is further determined by the ability to easily adjust the trajectory according to the visual 255 
feedback provided by the navigation platform and by the frameless setup of the stereotactic arm, in 256 
cases where the pathologist does not find the sample appropriate for final diagnosis.  257 
Among the 110 patients with a histological diagnosis of glioma, the specimen was useful to 258 
characterize the status of the mutation of IDH1/2 in 108 patients (98.2%) and in 103 patients it was 259 
wild-type. This shows that even in the molecular era, a needle biopsy is perfectly able to provide the 260 
correct amount of tissue useful for a molecular analysis. The status of mutation of IDH1 is an important 261 
prognostic factor and in the current tumor classification is the first characteristic that is used to 262 
correctly classify the glioma lesions [27].   263 
The analysis of the 1p/19q codeletion was performed according to the clinical, radiological and 264 
pathological characteristics. In our study, the 1p/19q codeletion was found in 39 patients with a 265 
presumptive glioma and the analysis was successfully performed in all the specimen analyzed. The 266 
presence of the 1p/19q codeletion is a good prognostic factor [12, 13] and drive the pathologist to the 267 
diagnosis of an oligodendroglial tumor with different implication in term of post-surgical adjuvant 268 
treatment and prognosis.  269 
The analysis of the status of methylation of the of the MGMT promoter gene was performed in 94 270 
patients with a presence of 60 patient with a methylated promoter and 34 patients without methylation. 271 
The information derived from the analysis of the  MGMT promoter methylation status from small-sized 272 
specimen obtained by stereotactic biopsies are reliable and it can be considered a representation of the 273 
whole tumor tested, as showed by Grasbon-Frodl et al [21] in patients undergoing multiple biopsies of 274 
the same tumor. Similarly, different tumor regions show  an homogeneous distribution and concordant 275 
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findings in the detection of the codeletion of the 1p/19q [23, 43] with misleading results only in 276 
presence of significant contamination of the sample (for example by blood or other contaminant).  277 
In our experience, the frameless stereotactic biopsy resulted a safe technique: we had only 12 (8.7%) 278 
cases of surgical complication in 140 patients and only 3 (2.1%) of them required a surgical 279 
intervention. In 1 case, we observed a cerebral abscess at the piking site successfully treated with 280 
medical therapy. We also observed 8 small asymptomatic hemorrhage detected only with the CT scan 281 
routinely performed after the procedure. These findings are in line with other work where the rate or 282 
complication vary from 0% to 20%  [15, 22, 28, 44]. Analyzing possible cause of complication, we did 283 
not find any correlation with age, KPF, site of tumor, tumor volume or other patients or tumors 284 
characteristics (all the p > 0.05). This data likely stems from the limited number of adverse events in 285 
our simple that cannot allow to reach the statistical significance. In fact, as showed by Malone et al. 286 
[30], analyzing big registry with more than 7.500 patients is possible to find some characteristic 287 
associated with hemorrhagic adverse events like old age, presence of edema, hydrocephalus and other.  288 
The mean time of stay in the operative room in our sample was 137.44 minutes (+/- 24.1) but analyzing 289 
the actually duration of the procedure it falls to 60.77 +/- 23.12 minutes. This mean time duration is 290 
similar to the other centers and series [20, 41] and is important because a short duration of the 291 
procedure is related to shorter duration of the anesthesia and a shorter exposure to infection.  292 
We also hypothesized that the occurrence of complications could have been related to the number of 293 
total procedures carried out in a single center in a given time; however, no statistically significant 294 
difference was observed dividing the current series into two halves, ruling out the hypothesis of an 295 
effect of the learning curve onto the likelihood of complications.  296 
 297 
Conclusion 298 
In the era of the integrated histologic and molecular diagnosis, the treatment of glial tumors, the most 299 
common intra-axial primitive lesions of the CNS, is strongly determined to their molecular profile. 300 
When a surgical open procedure is not possible, a stereotactic frameless biopsy is an important tool in 301 
the hands of the neurosurgeon. Our data shows that the stereotactic frameless biopsy is an efficient 302 
procedure to provide a molecular diagnosis that is currently essential for the correct management of the 303 
neuro-oncological patients. This yield could become even more relevant in the near future, when 304 
multiple therapeutic approaches should become available, such as immunological or cell-based 305 
therapies.  306 
 307 
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Table 1  467 
Lesions location  468 
 469 
 470 
 471 
 472 
 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
 483 
 484 
 485 
 486 
 487 
 488 
489 
Site No. (%) 
Side of the entry point  
     Left  84 (60) 
     Right 56 (40) 
Cerebral Lobe  
     Frontal 51 (36.4) 
     Temporal 23 (16.4) 
     Parietal 10 (7.1) 
     Occipital 4 (2.8) 
Corpus Callosum 27 (19.2) 
Diencephalon  9 (6.4) 
Basal Ganglia 7 (5) 
Cerebellum 9 (6.4) 
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Table 2  490 
Clinical characteristics  491 
 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
 510 
 511 
 512 
513 
Characteristics  
Age (%)  
<40 18 (12.8) 
40-65 68 (48.6) 
>65 54 (38.6) 
Mean Age (range) 58.68 (17-86) 
Sex (%)  
Male 73 (47.9) 
Female 67 (52.1) 
11-C-MET-PET available (%) 49 (35%) 
Median KPS before surgery (range) 90 (40-100) 
Median Length of hospital stay (IQR) 5 (4-8) 
Time in OR (mean +/- SD) 137.44 +/- 24.1 
Duration of surgery in minutes (mean +/- SD) 60.5 +/- 23.1 
Lesions volume in cm3 (mean +/- SD) 26.09 +/- 26.6 (range 0.56-98.83) 
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Table 3  514 
Histo-molecoular and bioptic results 515 
 516 
 517 
 518 
 519 
 520 
 521 
 522 
 523 
 524 
 525 
 526 
 527 
 528 
 529 
 530 
 531 
 532 
 533 
 534 
535 
Histological diagnostic yield (%) 131/140 (93.6) 
No. Of trajectories (%)  
1 137 (97.9) 
>1 3 (2.1) 
Mean Trajectories lenght in mm +/- SD 46.04 +/- 32.54 (range 8.5-140) 
Histological diagnosis   
     Glioma I/II/III/IV/NOS grade 1/6/15/76/12 (total 110) 
     Lymphoma  13 
     Metastasis 4 
     Abcess 2 
     Germ cell tumor 2 
     Unconclusive 9 
Molecular diagnosis in glioma patients  
  IDH-1 status obteinded (% of glioma) 108 (98,2) 
     Mutated  3 
     Wildtype 105 
  MGMT promoter methylation status (% of glioma) 96 (87.3) 
     Methylated 60 
     Unmethylated 36 
  1p/19q codelation (n° of glioma investigated) 6 (30) 
Surgical Complication (%)  
     Asymptomatic haemorrhage 8 (5.7) 
     Abscess 1 (0.7) 
     Surgical complication requiring surgery  3 (2.1) 
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 536 
Figures Caption 537 
Figure 1 538 
The flow chart describes the approach for newly diagnosed intra-axial lesions and the selection 539 
process of the study cohort. 540 
541 
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Figure 2 542 
Axial (A), coronal (B) and sagittal (C) post-contrast T1-weighted and 11-C-MET-PET CT scans (D-F) 543 
are co-registered before surgery and used for trajectory planning. The trajectory is showed (yellow), 544 
with the entry point located in the left middle frontal gyrus and the target, a deep presumptive high-545 
grade glioma, located in the basal ganglia area. The sampling window is showed in purple and allows 546 
the surgeon to check the part of the lesion is to be taken and analyzed by the pathologist. The 11C-547 
MET PET scans are fused to the other MRI scans to increase the likelihood of targeting the portion of 548 
the lesion with an enhanced methionine metabolism, corresponding to an increased cellular turn-over. 549 
The histological evaluation demonstrated a Glioblastoma (Grade IV WHO), IDH-1 mutated, MGMT 550 
promotor methylated (56%), proliferative fraction (Ki-67): 20%.  551 
 552 
